<DOC>
	<DOCNO>NCT02796222</DOCNO>
	<brief_summary>Recombinant factor VIII Fc ( rFVIIIFc ) recombinant factor IX Fc ( rFIXFc ) extend half-life coagulation factor approve Health Canada 2014 treatment severe hemophilia A B , respectively . The objective observational study describe change annual factor consumption , clinical patient-reported outcome patient switch recombinant factor VIII ( rFVIII ) recombinant factor IX ( rFIX ) rFVIIIFc/ rFIXFc Canada , explore clinician ' patient ' reason switch switching .</brief_summary>
	<brief_title>Factor Product Utilization Health Outcomes Patients With Hemophilia</brief_title>
	<detailed_description />
	<mesh_term>Hemophilia A</mesh_term>
	<mesh_term>Hemophilia B</mesh_term>
	<mesh_term>Factor VIII</mesh_term>
	<criteria>1 . Males â‰¥12 year age severe moderate congenital hemophilia A B ( baseline factor activity &lt; 5 % ) 2 . Ability understand purpose risk study provide sign date informed consent assent authorization use protect health information ( PHI ) accordance national local privacy regulation . 1 . Unable unwilling provide inform consent 2 . Patients exist bleed disorder hemophilia A B 3 . History hypersensitivity severe allergic reaction factor product 4 . Patients currently participate phase 13 study another factor replacement product 5 . Unable adhere study requirement base judgment Prescribing Physician ( e.g . unable enter accurate timely infusion bleeding record )</criteria>
	<gender>Male</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Hemophilia</keyword>
	<keyword>Recombinant factor VIII</keyword>
	<keyword>Recombinant factor VIII Fc</keyword>
	<keyword>Recombinant factor IX</keyword>
	<keyword>Patient-reported outcome</keyword>
	<keyword>Recombinant factor IX Fc</keyword>
</DOC>